Literature DB >> 1008989

Stimulation of autologous blood lymphocytes by malignant lymphoma cells and homogenates.

M E Ludgate, J Gough.   

Abstract

The blastogenic response to autologous blood lymphocytes to whole-cell suspensions and to homogenates obtained from malignant lymphoma tissue has been investigated. Spleens were obtained from patients in whom laparotomy was performed for staging of malignant lymphoma. Cell suspensions prepared from tumour nodules were treated with mitomycin C and allowed to react with separated autologous blood lymphocytes for 6 days. Lymphocyte stimulation was measured by liquid scintillation counting after exposure to 3H-TdR. Cultures were also prepared in which autologous lymphocytes were treated with spleen tumour homogenate. Control experiments used spleens from staging procedures in which no tumour deposits were present, and normal spleens removed incidentally during other operations. In the controls, the uptake of TdR was never more than twice that of unstimulated lymphocytes. Greater degrees of lymphocyte stimulation were seen in 6 out of 14 patients, using whole tumour cells, and in 7 out of 16 patients, using tumour homogenates. The results indicate an antigenic difference between tumour and host cells, and suggest that lymphocytes can react to a tumour-associated antigen.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1008989      PMCID: PMC2025238          DOI: 10.1038/bjc.1976.222

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Cellular immunity against tumor-associated antigens in humans: lymphocyte stimulation and skin reaction.

Authors:  R Vánky; E Klein; J Stjernswärd; U Nilsonne
Journal:  Int J Cancer       Date:  1974-08-15       Impact factor: 7.396

2.  Demonstration of cell-mediated immunity to human neoplasms of various histological types.

Authors:  I Hellström; K E Hellström; H O Sjögren; G A Warner
Journal:  Int J Cancer       Date:  1971-01-15       Impact factor: 7.396

3.  Possible immunological factors in human malignant melanoma in Uganda.

Authors:  M G Lewis
Journal:  Lancet       Date:  1967-10-28       Impact factor: 79.321

4.  In vitro lymphocyte stimulation by a soluble antigen from malignant melanoma.

Authors:  U W Jehn; L Nathanson; R S Schwartz; M Skinner
Journal:  N Engl J Med       Date:  1970-08-13       Impact factor: 91.245

5.  Demonstration of antibodies against human malignant melanoma by immunofluorescence.

Authors:  D L Morton; R A Malmgren; E C Holmes; A S Ketcham
Journal:  Surgery       Date:  1968-07       Impact factor: 3.982

6.  Cell migration inhibition in human lymphomas using lymph node and cell line antigens.

Authors:  M Braun; L Sen; A E Bachmann; A Pavlovsky
Journal:  Blood       Date:  1972-03       Impact factor: 22.113

7.  Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human breast carcinoma.

Authors:  J L McCoy; L F Jerome; J H Dean; G B Cannon; T C Alford; T Doering; R B Herberman
Journal:  J Natl Cancer Inst       Date:  1974-07       Impact factor: 13.506

8.  Hodgkin's disease; a correlation of histopathology with survival.

Authors:  J Gough
Journal:  Int J Cancer       Date:  1970-03-15       Impact factor: 7.396

9.  Cell-mediated immunity to human solid tumors: in vitro detection by lymphocyte blastogenic responses to cell-associated and solubilized tumor antigens.

Authors:  G M Mavligit; J U Gutterman; C M McBride; E M Hersh
Journal:  Natl Cancer Inst Monogr       Date:  1973-06

10.  Immunotherapy for acute myelogenous leukaemia.

Authors:  R L Powles; D Crowther; C J Bateman; M E Beard; T J McElwain; J Russell; T A Lister; J M Whitehouse; P F Wrigley; M Pike; P Alexander; G H Fairley
Journal:  Br J Cancer       Date:  1973-11       Impact factor: 7.640

View more
  1 in total

1.  Mixed isotype class II antigen expression. A novel class II molecule is expressed on a murine B cell lymphoma.

Authors:  J S Spencer; R T Kubo
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.